

FSG Invests in SAGA Diagnostics to Advance Precision Cancer Diagnostics

Lund, Sweden – April 25, 2023 – Fåhraeus Startup & Growth Fund II (FSG) today announces its investment in **SAGA Diagnostics**, a Swedish precision oncology company specialising in ultra-sensitive detection of circulating tumour DNA. The investment was made as part of a financing round led by **Segulah Medical Acceleration and Hadean Ventures**.

SAGA Diagnostics has developed proprietary methods to detect and measure tumour DNA in tissue and blood samples with **very high specificity and sensitivity**, enabling clinicians to monitor how patients respond to treatment. Founded in 2016 as a **spin-out from Lund University**, the company serves precision oncology and disease monitoring.

“SAGA Diagnostics sits exactly at the cross-section of technology and life science that defines FSG’s focus. Its ultra-sensitive approach to detecting tumour DNA has the potential to change how clinicians monitor cancer, and we are proud to support the team,” said **Linus Wiebe, General Partner and Managing Director at FSG**.

“This investment allows us to accelerate the clinical and commercial roll-out of our precision diagnostics. FSG’s backing and operational experience make them an ideal partner as we scale,” said **Peter Collins, CEO of SAGA Diagnostics**.

About SAGA Diagnostics

SAGA Diagnostics is a precision oncology company focused on ultra-sensitive detection of circulating tumour DNA and minimal residual disease. Founded in 2016 as a spin-out from Lund University, it offers molecular genetic testing of tissue and liquid biopsies to support cancer treatment decisions.

About Fåhraeus Startup & Growth (FSG)

Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations. **FSG Fund II is supported by the European Investment Fund (EIF)**.

For media inquiries

Linus Wiebe, GP and Managing Director, (FSG Fund II) | linus.wiebe@fsg.vc

Peter Collins, CEO, SAGA Diagnostics | peter.collins@sagadiagnostics.com